Navigation Links
Three Cetaphil(R) Products Earn Good Housekeeping Seal
Date:10/19/2009

FORT WORTH, Texas, Oct. 19 /PRNewswire/ -- Galderma Laboratories proudly announces that Cetaphil® Gentle Skin Cleanser, Cetaphil® Moisturizing Cream, and Cetaphil® UVA/UVB Defense SPF 50 have recently been granted the prestigious Good Housekeeping Seal after evaluation by the Good Housekeeping Research Institute.

The Good Housekeeping Seal was introduced in 1909 as one of the first "tested and approved" emblems in the U.S.

"It is a fantastic accomplishment for the Cetaphil brand to be backed by the Good Housekeeping Seal and further demonstrates our commitment to providing consumers gentle skin care for all skin types and conditions," said Cindy Kee, Senior Product Manager for Cetaphil® products.

"I recommend Cetaphil cleansers and moisturizers to my patients because it's a brand that I trust. I know that their products are non-irritating and effective, so I feel comfortable with my patients using them everyday," said board-certified dermatologist Dr. Ilyse Lefkowicz, M.D.

Cetaphil® Cleansers and Moisturizers are currently the #1 dermatologist and pediatrician recommended brand of cleansers and moisturizers. For more information on the Cetaphil® brand and its product offerings or to join the Cetaphil Skin Care Club® please visit www.cetaphil.com.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully-integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The company has a presence in 65 countries with over 1000 sales representatives and is committed to improving the health of skin with an extensive line of products across the world that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, medical solutions for skin senescence and skin cancers. With a research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities dedicated exclusively to dermatology. Leading worldwide dermatology brands include Differin®, Epiduo(TM), Oracea®, MetroGel® 1%, Rozex®, Clobex®, Vectical(TM), Tri-Luma®, Loceryl® and Cetaphil®. For more information about Galderma, visit www.galdermaUSA.com.

About Cetaphil

The Family of Cetaphil® Cleansers and Moisturizers is a line of dermatologist and pediatrician recommended skin care products specially formulated for all skin types. Cetaphil® products are developed to provide effective, gentle skin care and include: Cetaphil® Gentle Skin Cleanser, Cetaphil® Daily Facial Cleanser, Cetaphil® Gentle Cleansing Bar, Cetaphil® Antibacterial Gentle Cleansing Bar, Cetaphil® Moisturizing Lotion, Cetaphil® Moisturizing Cream, Cetaphil DailyAdvance Ultra Hydrating Lotion®, Cetaphil® Daily Facial Moisturizer SPF 15, Cetaphil® Therapeutic Hand Cream, Cetaphil® UVA/UVB Defense SPF 50. To learn more about Cetaphil® products and to join the Cetaphil Skin Care Club® visit www.cetaphil.com.

SOURCE Galderma Laboratories


'/>"/>
SOURCE Galderma Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling $10.7 Million of Annual Net Revenue
2. Cord Blood America Continues to Reduce Debt; Three Notes Retired
3. Novant Health Rolls Out MEDais Predictive Modeling Solution to Nine Hospitals in Three States
4. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
5. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
6. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
7. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
8. New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients Blood Sugar
9. Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries
10. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
11. Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... 2017 , ... Elisabete Miranda, president and CEO of ... magazine as one of its 2017 Enterprising Women of the Year, a prestigious ... that they have fast-growth businesses, mentor or actively support other women and girls ...
(Date:4/26/2017)... NJ (PRWEB) , ... April 26, 2017 , ... RawTrition ... an easy way to get nutrients from SUPERFOODS! , RawTrition is taking ... at the cellular level because the body recognizes its raw form (unlike the synthetically ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
Breaking Medicine News(10 mins):